HIV-1 vaccines

References

• UNAIDS Report on the Global AIDS Epidemic 2013. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf
   Google Scholar
• McCoy SI, Kangwende RA, Padian NS. Behavior change interventions to prevent HIV infection among women living in low and middle income countries: a systematic review. AIDS Behav 2010; 14:469 - 82; http://dx.doi.org/10.1007/s10461-009-9644-9; PMID: 19949847
   PubMed Web of Science ®Google Scholar
• Dutta A, Wirtz AL, Baral S, Beyrer C, Cleghorn FR. Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Curr Opin HIV AIDS 2012; 7:362 - 8; http://dx.doi.org/10.1097/COH.0b013e328354a0b5; PMID: 22647588
   PubMed Web of Science ®Google Scholar
• Wamai RG, Morris BJ, Bailis SA, Sokal D, Klausner JD, Appleton R, Sewankambo N, Cooper DA, Bongaarts J, de Bruyn G, et al. Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. J Int AIDS Soc 2011; 14:49; http://dx.doi.org/10.1186/1758-2652-14-49; PMID: 22014096
   PubMed Web of Science ®Google Scholar
• Chi BH, Adler MR, Bolu O, Mbori-Ngacha D, Ekouevi DK, Gieselman A, Chipato T, Luo C, Phelps BR, McClure C, et al. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President’s Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr 2012; 60:Suppl 3 S78 - 87; http://dx.doi.org/10.1097/QAI.0b013e31825f3284; PMID: 22797744
   PubMed Web of Science ®Google Scholar
• Kim SC, Becker S, Dieffenbach C, Hanewall BS, Hankins C, Lo YR, Mellors JW, O’Reilly K, Paxton L, Roffenbender JS, et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc 2010; 13:24; http://dx.doi.org/10.1186/1758-2652-13-24; PMID: 20624303
   PubMed Web of Science ®Google Scholar
• Cohen MS, Holmes C, Padian N, Wolf M, Hirnschall G, Lo YR, Goosby E. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. Health Aff (Millwood) 2012; 31:1439 - 49; http://dx.doi.org/10.1377/hlthaff.2012.0250; PMID: 22778333
   PubMed Web of Science ®Google Scholar
• Krakower D, Mayer KH. Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications. Curr HIV/AIDS Rep 2011; 8:241 - 8; http://dx.doi.org/10.1007/s11904-011-0094-4; PMID: 22002729
   PubMedGoogle Scholar
• Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS 2013; 27:447 - 58; http://dx.doi.org/10.1097/QAD.0b013e32835ca2dd; PMID: 23296196
   PubMed Web of Science ®Google Scholar
• Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, Bartos M, Katabira E, Bertozzi SM, Schwartländer B, Cohen MS. HIV prevention transformed: the new prevention research agenda. Lancet 2011; 378:269 - 78; http://dx.doi.org/10.1016/S0140-6736(11)60877-5; PMID: 21763938
   PubMed Web of Science ®Google Scholar
• O’Connell RJ, Kim JH, Corey L, Michael NL. Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med 2012; 2:a007351; http://dx.doi.org/10.1101/cshperspect.a007351; PMID: 23209178
   PubMedGoogle Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al, MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209 - 20; http://dx.doi.org/10.1056/NEJMoa0908492; PMID: 19843557
   PubMed Web of Science ®Google Scholar
• Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012; 12:531 - 7; http://dx.doi.org/10.1016/S1473-3099(12)70088-9; PMID: 22652344
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275 - 86; http://dx.doi.org/10.1056/NEJMoa1113425; PMID: 22475592
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Habib RE, Baglyos L, Meric C, Plotkin S, Dodet B, Corey L, Tartaglia J. Use of predictive markers of HIV disease progression in vaccine trials. Vaccine 2009; 27:1997 - 2015; http://dx.doi.org/10.1016/j.vaccine.2009.01.039; PMID: 19200450
   PubMed Web of Science ®Google Scholar
• Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M, Katlama C, et al, International AIDS Society Scientific Working Group on HIV Cure. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607 - 14; http://dx.doi.org/10.1038/nri3262; PMID: 22814509
   PubMed Web of Science ®Google Scholar
• McBurney SP, Ross TM. Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines 2008; 7:1405 - 17; http://dx.doi.org/10.1586/14760584.7.9.1405; PMID: 18980542
   PubMed Web of Science ®Google Scholar
• Hemelaar J, Gouws E, Ghys PD, Osmanov S, WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679 - 89; http://dx.doi.org/10.1097/QAD.0b013e328342ff93; PMID: 21297424
   PubMed Web of Science ®Google Scholar
• Koff WC. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 2012; 30:4310 - 5; http://dx.doi.org/10.1016/j.vaccine.2011.11.014; PMID: 22100891
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009; 15:866 - 70; PMID: 19525964
   PubMed Web of Science ®Google Scholar
• Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012; 18:1688 - 92; http://dx.doi.org/10.1038/nm.2985; PMID: 23086475
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16:1389 - 91; http://dx.doi.org/10.1038/nm1210-1389; PMID: 21135852
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654 - 65; http://dx.doi.org/10.1086/428404; PMID: 15688278
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005; 192:974 - 83; http://dx.doi.org/10.1086/432734; PMID: 16107949
   PubMed Web of Science ®Google Scholar
• Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D’Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010; 202:595 - 605; http://dx.doi.org/10.1086/654816; PMID: 20608874
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666 - 77; http://dx.doi.org/10.1086/428405; PMID: 15688279
   PubMed Web of Science ®Google Scholar
• Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178:6596 - 603; PMID: 17475891
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K, Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661 - 71; http://dx.doi.org/10.1086/508748; PMID: 17109337
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al, Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881 - 93; http://dx.doi.org/10.1016/S0140-6736(08)61591-3; PMID: 19012954
   PubMed Web of Science ®Google Scholar
• McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, et al, Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894 - 905; http://dx.doi.org/10.1016/S0140-6736(08)61592-5; PMID: 19012957
   PubMed Web of Science ®Google Scholar
• Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, et al, HVTN 503/Phambili study team. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11:507 - 15; http://dx.doi.org/10.1016/S1473-3099(11)70098-6; PMID: 21570355
   PubMed Web of Science ®Google Scholar
• Gray GE, Metch B, Churchyard G, Mlisana K, Nchabeleng M, Allen M, Moodie Z, Kublin J, Bekker LG, HVTN 503 team. Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?. Vaccine 2013; 31:2089 - 96; http://dx.doi.org/10.1016/j.vaccine.2013.01.031; PMID: 23370155
   PubMed Web of Science ®Google Scholar
• D’Souza MP, Frahm N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 2010; 24:803 - 9; http://dx.doi.org/10.1097/QAD.0b013e3283379712; PMID: 20168203
   PubMed Web of Science ®Google Scholar
• Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, et al, Step/HVTN 504 Study Team. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 2012; 206:258 - 66; http://dx.doi.org/10.1093/infdis/jis342; PMID: 22561365
   PubMed Web of Science ®Google Scholar
• Koblin BA, Mayer KH, Noonan E, Wang CY, Marmor M, Sanchez J, Brown SJ, Robertson MN, Buchbinder SP. Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step study. J Acquir Immune Defic Syndr 2012; 60:405 - 13; http://dx.doi.org/10.1097/QAI.0b013e31825325aa; PMID: 22421748
   PubMed Web of Science ®Google Scholar
• Curlin ME, Cassis-Ghavami F, Magaret AS, Spies GA, Duerr A, Celum CL, Sanchez JL, Margolick JB, Detels R, McElrath MJ, et al. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS 2011; 25:153 - 8; http://dx.doi.org/10.1097/QAD.0b013e328342115c; PMID: 21150554
   PubMed Web of Science ®Google Scholar
• Cheng C, Wang L, Gall JG, Nason M, Schwartz RM, McElrath MJ, DeRosa SC, Hural J, Corey L, Buchbinder SP, et al. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS One 2012; 7:e33969; http://dx.doi.org/10.1371/journal.pone.0033969; PMID: 22496775
   PubMed Web of Science ®Google Scholar
• Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011; 17:366 - 71; http://dx.doi.org/10.1038/nm.2316; PMID: 21358627
   PubMed Web of Science ®Google Scholar
• Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, Gilbert P, Loufty M, Mehrotra D, Duerr A, Step Study Protocol Team. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis 2011; 203:765 - 72; http://dx.doi.org/10.1093/infdis/jiq114; PMID: 21343146
   PubMed Web of Science ®Google Scholar
• Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, Cole S, McElrath MJ, Shiver JW, Casimiro DR, Corey L, et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One 2011; 6:e20479; http://dx.doi.org/10.1371/journal.pone.0020479; PMID: 21695251
   PubMed Web of Science ®Google Scholar
• Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008; 14:617 - 21; http://dx.doi.org/10.1038/nm.f.1759; PMID: 18535579
   PubMed Web of Science ®Google Scholar
• Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr., Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, et al. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 2012; 30:4465 - 75; http://dx.doi.org/10.1016/j.vaccine.2012.04.082; PMID: 22569124
   PubMed Web of Science ®Google Scholar
• Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, et al. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 2012; 86:2239 - 50; http://dx.doi.org/10.1128/JVI.06175-11; PMID: 22156519
   PubMed Web of Science ®Google Scholar
• Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med 2011; 17:1194 - 5; http://dx.doi.org/10.1038/nm.2529; PMID: 21988996
   PubMed Web of Science ®Google Scholar
• Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, et al, VRC 009 Study Team, VRC 010 Study Team. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010; 5:e9015; http://dx.doi.org/10.1371/journal.pone.0009015; PMID: 20126394
   PubMed Web of Science ®Google Scholar
• Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, Shaffer D, Eller LA, Kibaya R, Eller MA, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 2010; 201:600 - 7; http://dx.doi.org/10.1086/650299; PMID: 20078213
   PubMed Web of Science ®Google Scholar
• Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, Adams EM, Graham BS, Koup RA, Bailer RT, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010; 5:e12873; http://dx.doi.org/10.1371/journal.pone.0012873; PMID: 20877623
   PubMed Web of Science ®Google Scholar
• Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, et al, NIAID HIV Vaccine Trials Network. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011; 6:e21225; http://dx.doi.org/10.1371/journal.pone.0021225; PMID: 21857901
   PubMed Web of Science ®Google Scholar
• Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, et al, HVTN 505 Study Team. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369:2083 - 92; http://dx.doi.org/10.1056/NEJMoa1310566; PMID: 24099601
   PubMed Web of Science ®Google Scholar
• Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim SY, Yeh WW, Asmal M, Gelman RS, Shen L, et al. Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med 2011; 3:81ra36; http://dx.doi.org/10.1126/scitranslmed.3002351; PMID: 21543722
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Johnson MJ, Price DA, Wolinsky DI, Almeida JR, Petrovas C, Nason M, Yeh WW, Shen L, Roederer M, et al. Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection. J Virol 2012; 86:5877 - 84; http://dx.doi.org/10.1128/JVI.00315-12; PMID: 22419810
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayapan S, Kaewkungwal J, et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One 2011; 6:e27837; http://dx.doi.org/10.1371/journal.pone.0027837; PMID: 22205930
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011; 203:969 - 75; http://dx.doi.org/10.1093/infdis/jiq152; PMID: 21402548
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Premsri N, Namwat C, Bowonwatanuwong C, Li SS, Kaewkungkal J, Trichavaroj R, Churikanont N, et al. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis 2013; 207:1195 - 205; http://dx.doi.org/10.1093/infdis/jis478; PMID: 22837492
   PubMed Web of Science ®Google Scholar
• de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, et al, Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012; 188:5166 - 76; http://dx.doi.org/10.4049/jimmunol.1102756; PMID: 22529301
   PubMed Web of Science ®Google Scholar
• Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, et al, Thai AIDS Vaccine Evaluation Group, Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005; 23:2522 - 9; http://dx.doi.org/10.1016/j.vaccine.2004.10.028; PMID: 15752839
   PubMed Web of Science ®Google Scholar
• Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012; 86:11521 - 32; http://dx.doi.org/10.1128/JVI.01023-12; PMID: 22896626
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012; 206:431 - 41; http://dx.doi.org/10.1093/infdis/jis367; PMID: 22634875
   PubMed Web of Science ®Google Scholar
• Paris R, Bejrachandra S, Thongcharoen P, Nitayaphan S, Pitisuttithum P, Sambor A, Gurunathan S, Francis D, Ratto-Kim S, Karnasuta C, et al, Thai AIDS Vaccine Evaluation Group. HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E. Vaccine 2012; 30:832 - 6; http://dx.doi.org/10.1016/j.vaccine.2011.11.002; PMID: 22085554
   PubMed Web of Science ®Google Scholar
• Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, et al, MOPH TAVEG Collaboration. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012; 28:1444 - 57; http://dx.doi.org/10.1089/aid.2012.0103; PMID: 23035746
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 2013; 8:e53629; http://dx.doi.org/10.1371/journal.pone.0053629; PMID: 23349725
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Decamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014; 9:e87572; http://dx.doi.org/10.1371/journal.pone.0087572; PMID: 24504509
   PubMed Web of Science ®Google Scholar
• Tomaras G, Shen X, Seaton K, Janes H, Grove D, Decamp A, et al. Vaccine Induced Antibody Responses in HVTN 505, a Phase IIb HIV-1 Efficacy Trial. [PL04.04] AIDS Res Hum Retroviruses 2013; 29:A-168
   Web of Science ®Google Scholar
• Rolland M, Edlefsen PT, Gottardo R, Montefiori DC, Zolla-Pazner S, Moody A, et al. Genetic and immunological evidence for a role of Env-V3 antibodies in the RV144 trial. [P03-73 LB] AIDS Res Hum Retroviruses 2013; 29:A-168
   Web of Science ®Google Scholar
• Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 2013; 8:e75665; http://dx.doi.org/10.1371/journal.pone.0075665; PMID: 24086607
   PubMed Web of Science ®Google Scholar
• Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490:417 - 20; http://dx.doi.org/10.1038/nature11519; PMID: 22960785
   PubMed Web of Science ®Google Scholar
• Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013; 38:176 - 86; http://dx.doi.org/10.1016/j.immuni.2012.11.011; PMID: 23313589
   PubMed Web of Science ®Google Scholar
• Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao HX, Fong Y, Alam SM, Overman RG, Denny T, et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol 2013; 87:7828 - 36; http://dx.doi.org/10.1128/JVI.02737-12; PMID: 23658446
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54:1615 - 7; http://dx.doi.org/10.1093/cid/cis238; PMID: 22437237
   PubMed Web of Science ®Google Scholar
• Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011; 85:7029 - 36; http://dx.doi.org/10.1128/JVI.00171-11; PMID: 21543485
   PubMed Web of Science ®Google Scholar
• Moody MA, Yates NL, Amos JD, Drinker MS, Eudailey JA, Gurley TC, Marshall DJ, Whitesides JF, Chen X, Foulger A, et al. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol 2012; 86:7496 - 507; http://dx.doi.org/10.1128/JVI.00426-12; PMID: 22553329
   PubMed Web of Science ®Google Scholar
• Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 2013; 110:9019 - 24; http://dx.doi.org/10.1073/pnas.1301456110; PMID: 23661056
   PubMed Web of Science ®Google Scholar
• Nakamura GR, Fonseca DP, O’Rourke SM, Vollrath AL, Berman PW. Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding. PLoS One 2012; 7:e39045; http://dx.doi.org/10.1371/journal.pone.0039045; PMID: 22720026
   PubMed Web of Science ®Google Scholar
• Mayr LM, Cohen S, Spurrier B, Kong X-P, Zolla-Pazner S. Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. PLoS One 2013; 8:e70859; http://dx.doi.org/10.1371/journal.pone.0070859; PMID: 23923028
   PubMed Web of Science ®Google Scholar
• Rao M, Peachman KK, Kim J, Gao G, Alving CR, Michael NL, Rao VB. HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. Curr HIV Res 2013; 11:427 - 38; http://dx.doi.org/10.2174/1570162X113116660064; PMID: 24191938
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Patel GB, Mandava M, Berman PW, Belshe RB, National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 1999; 15:921 - 30; http://dx.doi.org/10.1089/088922299310638; PMID: 10408729
   PubMed Web of Science ®Google Scholar
• Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses 2010; 26:445 - 58; http://dx.doi.org/10.1089/aid.2009.0223; PMID: 20377426
   PubMed Web of Science ®Google Scholar
• Roussilhon C, Oeuvray C, Müller-Graf C, Tall A, Rogier C, Trape JF, Theisen M, Balde A, Pérignon JL, Druilhe P. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 2007; 4:e320; http://dx.doi.org/10.1371/journal.pmed.0040320; PMID: 18001147
   PubMed Web of Science ®Google Scholar
• Tebo AE, Kremsner PG, Luty AJ. Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro. Exp Parasitol 2001; 98:20 - 8; http://dx.doi.org/10.1006/expr.2001.4619; PMID: 11426948
   PubMed Web of Science ®Google Scholar
• Kam YW, Simarmata D, Chow A, Her Z, Teng TS, Ong EK, Rénia L, Leo YS, Ng LF. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis 2012; 205:1147 - 54; http://dx.doi.org/10.1093/infdis/jis033; PMID: 22389226
   PubMed Web of Science ®Google Scholar
• Ljunggren K, Broliden PA, Morfeldt-Månson L, Jondal M, Wahren B. IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol 1988; 73:343 - 7; PMID: 3208446
   PubMed Web of Science ®Google Scholar
• Yates NL, Liao HX, Fong Y, De Camp A, Vandergrift NA, Alam MS, et al. HIV-1 Env V1/V2 IgG3 Responses Correlate with Decreased Transmission Risk in the RV144 2 Trial and Distinguish Vaccine-Elicited Humoral Responses from the VAX003 Vaccine Trial. Sci Transl Med 2014; forthcoming
   PubMed Web of Science ®Google Scholar
• Teigler JE, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH. The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol 2014; 88:1809 14; http://dx.doi.org/10.1128/JVI.02386-13; PMID: 24257612
   PubMed Web of Science ®Google Scholar
• Forthal D, Hope TJ, Alter G. New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS 2013; 8:393 - 401; http://dx.doi.org/10.1097/COH.0b013e328363d486; PMID: 23924999
   PubMed Web of Science ®Google Scholar
• Vargas-Inchaustegui DA, Robert-Guroff M. Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention. Curr HIV Res 2013; 11:407 - 20; http://dx.doi.org/10.2174/1570162X113116660063; PMID: 24191937
   PubMed Web of Science ®Google Scholar
• Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, et al. Association of FcγRIIC Polymorphism with Vaccine Efficacy and Correlates of HIV-1 Infection Risk in RV144. [P06-20 LB] AIDS Res Hum Retroviruses 2013; 29:A-168
   Web of Science ®Google Scholar
• Van Rompay KK, Abel K, Lawson JR, Singh RP, Schmidt KA, Evans T, Earl P, Harvey D, Franchini G, Tartaglia J, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005; 38:124 - 34; http://dx.doi.org/10.1097/00126334-200502010-00002; PMID: 15671796
   PubMed Web of Science ®Google Scholar
• Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, Ferrari G, Pal R, Ferrari MG, Whitney S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol 2013; 87:1708 - 19; http://dx.doi.org/10.1128/JVI.02544-12; PMID: 23175374
   PubMed Web of Science ®Google Scholar
• Liyanage NP, Pegu P, Gordon S, Cameron M, Foulds K, Doster M, et al. RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues. Retrovirology 2012; 9:Suppl 2 O14; http://dx.doi.org/10.1186/1742-4690-9-S2-O14
   Google Scholar
• Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89 - 93; http://dx.doi.org/10.1038/nature10766; PMID: 22217938
   PubMed Web of Science ®Google Scholar
• Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 2014; 505:502 8; http://dx.doi.org/10.1038/nature12893; PMID: 24352234
   PubMed Web of Science ®Google Scholar
• Freel SA, Saunders KO, Tomaras GD. CD8(+)T-cell-mediated control of HIV-1 and SIV infection. Immunol Res 2011; 49:135 - 46; http://dx.doi.org/10.1007/s12026-010-8177-7; PMID: 21170741
   PubMed Web of Science ®Google Scholar
• McDermott AB, Koup RA. CD8(+) T cells in preventing HIV infection and disease. AIDS 2012; 26:1281 - 92; http://dx.doi.org/10.1097/QAD.0b013e328353bcaf; PMID: 22441256
   PubMed Web of Science ®Google Scholar
• Mudd PA, Martins MA, Ericsen AJ, Tully DC, Power KA, Bean AT, Piaskowski SM, Duan L, Seese A, Gladden AD, et al. Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 2012; 491:129 - 33; http://dx.doi.org/10.1038/nature11443; PMID: 23023123
   PubMed Web of Science ®Google Scholar
• Winstone N, Wilson AJ, Morrow G, Boggiano C, Chiuchiolo MJ, Lopez M, Kemelman M, Ginsberg AA, Mullen K, Coleman JW, et al. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J Virol 2011; 85:9578 - 87; http://dx.doi.org/10.1128/JVI.05060-11; PMID: 21734035
   PubMed Web of Science ®Google Scholar
• Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87 - 91; http://dx.doi.org/10.1038/nature07469; PMID: 18997770
   PubMed Web of Science ®Google Scholar
• Li H, Liu J, Carville A, Mansfield KG, Lynch D, Barouch DH. Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys. J Virol 2011; 85:11007 - 15; http://dx.doi.org/10.1128/JVI.05346-11; PMID: 21917969
   PubMed Web of Science ®Google Scholar
• Vaccari M, Keele BF, Bosinger SE, Doster MN, Ma ZM, Pollara J, Hryniewicz A, Ferrari G, Guan Y, Forthal DN, et al. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol 2013; 87:3538 - 48; http://dx.doi.org/10.1128/JVI.02863-12; PMID: 23325681
   PubMed Web of Science ®Google Scholar
• Bett AJ, Dubey SA, Mehrotra DV, Guan L, Long R, Anderson K, Collins K, Gaunt C, Fernandez R, Cole S, et al. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Vaccine 2010; 28:7881 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.09.079; PMID: 20937317
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Ahlers JD. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development. Curr Top Microbiol Immunol 2012; 354:157 - 79; http://dx.doi.org/10.1007/82_2010_119; PMID: 21203884
   PubMed Web of Science ®Google Scholar
• Masopust D, Picker LJ. Hidden memories: frontline memory T cells and early pathogen interception. J Immunol 2012; 188:5811 - 7; http://dx.doi.org/10.4049/jimmunol.1102695; PMID: 22675215
   PubMed Web of Science ®Google Scholar
• Hansen SG, Piatak M Jr., Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013; 502:100 - 4; http://dx.doi.org/10.1038/nature12519; PMID: 24025770
   PubMed Web of Science ®Google Scholar
• Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523 - 7; http://dx.doi.org/10.1038/nature10003; PMID: 21562493
   PubMed Web of Science ®Google Scholar
• Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, Siess D, Axthelm MK, Nelson JA, Jarvis MA, Picker LJ, et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 2010; 328:102 - 6; http://dx.doi.org/10.1126/science.1185350; PMID: 20360110
   PubMed Web of Science ®Google Scholar
• Genescà M, Skinner PJ, Bost KM, Lu D, Wang Y, Rourke TL, Haase AT, McChesney MB, Miller CJ. Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol 2008; 1:219 - 28; http://dx.doi.org/10.1038/mi.2008.6; PMID: 19079181
   PubMed Web of Science ®Google Scholar
• Genescà M, Ma ZM, Wang Y, Assaf B, Qureshi H, Fritts L, Huang Y, McChesney MB, Miller CJ. Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge. J Virol 2012; 86:9188 - 200; http://dx.doi.org/10.1128/JVI.00532-12; PMID: 22696662
   PubMed Web of Science ®Google Scholar
• Lu W, Chen S, Lai C, Guo W, Fu L, Andrieu JM. Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep 2012; 2:1736 - 46; http://dx.doi.org/10.1016/j.celrep.2012.11.016; PMID: 23260669
   PubMed Web of Science ®Google Scholar
• Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal DN, Sattentau QJ, et al, CAVD Project Group. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 2013; 27:F13 - 20; http://dx.doi.org/10.1097/QAD.0b013e328360eac6; PMID: 23775002
   PubMed Web of Science ®Google Scholar
• Excler JL, Tomaras GD, Russell ND. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 2013; 8:421 - 31; http://dx.doi.org/10.1097/COH.0b013e3283632c26; PMID: 23743791
   PubMed Web of Science ®Google Scholar
• Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 2012; 12:396 - 407; http://dx.doi.org/10.1016/j.chom.2012.09.008; PMID: 23084910
   PubMed Web of Science ®Google Scholar
• Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS 2012; 26:1293 - 302; http://dx.doi.org/10.1097/QAD.0b013e32835474d2; PMID: 22706011
   PubMed Web of Science ®Google Scholar
• Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, et al. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 2013; 87:1554 - 68; http://dx.doi.org/10.1128/JVI.00718-12; PMID: 23175357
   PubMed Web of Science ®Google Scholar
• Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, Mouz N, Amacker M, Chalifour A, Diomede L, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34:269 - 80; http://dx.doi.org/10.1016/j.immuni.2011.01.015; PMID: 21315623
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Maes C, Clement F, van Engelenburg F, van den Dobbelsteen M, Adler M, Amacker M, Lopalco L, Bomsel M, Chalifour A, et al. Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One 2013; 8:e55438; http://dx.doi.org/10.1371/journal.pone.0055438; PMID: 23437055
   PubMed Web of Science ®Google Scholar
• Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15:901 - 6; http://dx.doi.org/10.1038/nm.1967; PMID: 19448633
   PubMed Web of Science ®Google Scholar
• Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2011; 481:81 - 4; http://dx.doi.org/10.1038/nature10660; PMID: 22139420
   PubMed Web of Science ®Google Scholar
• Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, An DS, Baltimore D. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014; 20:296 - 300; http://dx.doi.org/10.1038/nm.3471; PMID: 24509526
   PubMed Web of Science ®Google Scholar
• Létourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, Korber B, McMichael AJ, et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007; 2:e984; http://dx.doi.org/10.1371/journal.pone.0000984; PMID: 17912361
   PubMed Web of Science ®Google Scholar
• Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, et al. Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Mol Ther 2014; 22:464 75; http://dx.doi.org/10.1038/mt.2013.248; PMID: 24166483
   PubMed Web of Science ®Google Scholar
• Koopman G, Beenhakker N, Nieuwenhuis I, Doxiadis G, Mooij P, Drijfhout JW, Koestler J, Hanke T, Fagrouch Z, Verschoor EJ, et al. DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS 2013; forthcoming http://dx.doi.org/10.1097/QAD.0000000000000047; PMID: 24105029
   PubMed Web of Science ®Google Scholar
• Stephenson KE, SanMiguel A, Simmons NL, Smith K, Lewis MG, Szinger JJ, Korber B, Barouch DH. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol 2012; 86:11434 - 40; http://dx.doi.org/10.1128/JVI.01779-12; PMID: 22896617
   PubMed Web of Science ®Google Scholar
• Barouch DH, O’Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010; 16:319 - 23; http://dx.doi.org/10.1038/nm.2089; PMID: 20173752
   PubMed Web of Science ®Google Scholar
• Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 2013; 155:531 - 9; http://dx.doi.org/10.1016/j.cell.2013.09.061; PMID: 24243013
   PubMed Web of Science ®Google Scholar
• Penaloza-MacMaster P, Provine NM, Ra J, Borducchi EN, McNally A, Simmons NL, Iampietro MJ, Barouch DH. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol 2013; 87:1373 - 84; http://dx.doi.org/10.1128/JVI.02058-12; PMID: 23152535
   PubMed Web of Science ®Google Scholar
• Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 2012; 7:e40385; http://dx.doi.org/10.1371/journal.pone.0040385; PMID: 22808149
   PubMed Web of Science ®Google Scholar
• Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011; 6:e19252; http://dx.doi.org/10.1371/journal.pone.0019252; PMID: 21603651
   PubMed Web of Science ®Google Scholar
• Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M, et al, NIAID HIV Vaccine Trials Network. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012; 7:e29231; http://dx.doi.org/10.1371/journal.pone.0029231; PMID: 22242162
   PubMed Web of Science ®Google Scholar
• Fukazawa Y, Park H, Cameron MJ, Lefebvre F, Lum R, Coombes N, Mahyari E, Hagen SI, Bae JY, Reyes MD 3rd, et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 2012; 18:1673 - 81; http://dx.doi.org/10.1038/nm.2934; PMID: 22961108
   PubMed Web of Science ®Google Scholar
• Parks CL, Picker LJ, King CR. Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 2013; 8:402 - 11; http://dx.doi.org/10.1097/COH.0b013e328363d389; PMID: 23925000
   PubMed Web of Science ®Google Scholar
• Liu L, Hao Y, Luo Z, Huang Y, Hu X, Liu Y, Shao Y. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization. Vaccine 2012; 30:4135 - 43; http://dx.doi.org/10.1016/j.vaccine.2012.04.075; PMID: 22561314
   PubMed Web of Science ®Google Scholar
• DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, Charurat M, Harris I, Galmin L, Pal R. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A 2007; 104:17477 - 82; http://dx.doi.org/10.1073/pnas.0707399104; PMID: 17956985
   PubMed Web of Science ®Google Scholar
• Shukair SA, Allen SA, Cianci GC, Stieh DJ, Anderson MR, Baig SM, Gioia CJ, Spongberg EJ, Kauffman SM, McRaven MD, et al. Human cervicovaginal mucus contains an activity that hinders HIV-1 movement. Mucosal Immunol 2013; 6:427 - 34; http://dx.doi.org/10.1038/mi.2012.87; PMID: 22990624
   PubMed Web of Science ®Google Scholar
• Fahrbach KM, Malykhina O, Stieh DJ, Hope TJ. Differential binding of IgG and IgA to mucus of the female reproductive tract. PLoS One 2013; 8:e76176; http://dx.doi.org/10.1371/journal.pone.0076176; PMID: 24098437
   PubMed Web of Science ®Google Scholar
• Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, Shattock RJ. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006; 20:1237 - 45; http://dx.doi.org/10.1097/01.aids.0000232230.96134.80; PMID: 16816551
   PubMed Web of Science ®Google Scholar
• Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature’s pathways. Immunol Rev 2013; 254:225 - 44; http://dx.doi.org/10.1111/imr.12075; PMID: 23772623
   PubMed Web of Science ®Google Scholar
• Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, et al, NISC Comparative Sequencing Program. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496:469 - 76; http://dx.doi.org/10.1038/nature12053; PMID: 23552890
   PubMed Web of Science ®Google Scholar
• Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013; 342:1477 - 83; http://dx.doi.org/10.1126/science.1245625; PMID: 24179159
   PubMed Web of Science ®Google Scholar
• Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med 2011; 17:108 - 16; http://dx.doi.org/10.1016/j.molmed.2010.10.008; PMID: 21112250
   PubMed Web of Science ®Google Scholar
• Sundling C, Martinez P, Soldemo M, Spångberg M, Bengtsson KL, Stertman L, Forsell MN, Karlsson Hedestam GB. Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting. J Infect Dis 2013; 207:426 - 31; http://dx.doi.org/10.1093/infdis/jis696; PMID: 23162135
   PubMed Web of Science ®Google Scholar
• Streeck H, D’Souza MP, Littman DR, Crotty S. Harnessing CD4⁺ T cell responses in HIV vaccine development. Nat Med 2013; 19:143 - 9; http://dx.doi.org/10.1038/nm.3054; PMID: 23389614
   PubMed Web of Science ®Google Scholar
• Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke MA, Arlehamn CL, Su LF, Cubas R, Davis MM, Sette A, et al, International AIDS Vaccine Initiative Protocol C Principal Investigators. Human circulating PD-⁺1CXCR3⁻CXCR5⁺ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013; 39:758 - 69; http://dx.doi.org/10.1016/j.immuni.2013.08.031; PMID: 24035365
   PubMed Web of Science ®Google Scholar
• Moon JJ, Suh H, Bershteyn A, Stephan MT, Liu H, Huang B, Sohail M, Luo S, Um SH, Khant H, et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011; 10:243 - 51; http://dx.doi.org/10.1038/nmat2960; PMID: 21336265
   PubMed Web of Science ®Google Scholar
• Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A 2012; 109:1080 - 5; http://dx.doi.org/10.1073/pnas.1112648109; PMID: 22247289
   PubMed Web of Science ®Google Scholar
• Deenick EK, Chan A, Ma CS, Gatto D, Schwartzberg PL, Brink R, Tangye SG. Follicular helper T cell differentiation requires continuous antigen presentation that is independent of unique B cell signaling. Immunity 2010; 33:241 - 53; http://dx.doi.org/10.1016/j.immuni.2010.07.015; PMID: 20691615
   PubMed Web of Science ®Google Scholar
• Nutt SL, Tarlinton DM. Germinal center B and follicular helper T cells: siblings, cousins or just good friends?. Nat Immunol 2011; 12:472 - 7; http://dx.doi.org/10.1038/ni.2019; PMID: 21739669
   PubMed Web of Science ®Google Scholar
• Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, Sun C, Chen Y, Yeh WW, Letvin NL, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206:1117 - 34; http://dx.doi.org/10.1084/jem.20082831; PMID: 19414559
   PubMed Web of Science ®Google Scholar
• Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552 - 7; http://dx.doi.org/10.1073/pnas.0802203105; PMID: 18490657
   PubMed Web of Science ®Google Scholar
• Tager AM, Pensiero M, Allen TM. Recent advances in humanized mice: accelerating the development of an HIV vaccine. J Infect Dis 2013; 208:Suppl 2 S121 - 4; http://dx.doi.org/10.1093/infdis/jit451; PMID: 24151317
   PubMedGoogle Scholar
• Esparza J. Solid vaccine protection against SIV in rhesus monkeys provides proof-of-concept for further evaluation of a novel HIV vaccine approach in humans. Expert Rev Vaccines 2012; 11:539 - 42; http://dx.doi.org/10.1586/erv.12.21; PMID: 22827240
   PubMed Web of Science ®Google Scholar
• Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, Bartos M, Ghys PD, Opuni M, Barr D, et al, Investment Framework Study Group. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011; 377:2031 - 41; http://dx.doi.org/10.1016/S0140-6736(11)60702-2; PMID: 21641026
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva 2001.
   Google Scholar
• Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA. Accelerating next-generation vaccine development for global disease prevention. Science 2013; 340:1232910; http://dx.doi.org/10.1126/science.1232910; PMID: 23723240
   PubMed Web of Science ®Google Scholar